Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Piacenza – page 23

667 clinical trials in Piacenza, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Piacenza at a glance
667
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

667 trials in Piacenza

Open in trial search

Parkinson's disease

Not yet recruiting

A study to test if BHV-8000 is effective and safe for adults with early Parkinson's disease

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ioflupane (123I)
  • Sponsor:Biohaven Therapeutics Ltd.

Non-small cell lung cancer

Not yet recruiting

Study of N-803, tislelizumab and docetaxel combination versus docetaxel alone for patients with advanced or metastatic non-small cell lung cancer resistant to immune checkpoint inhibitors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Immunitybio Inc.

Bronchiectasis

Not yet recruiting

Efficacy and safety of galvokimig in adults with non‑cystic fibrosis bronchiectasis: a randomized, double‑blind, placebo‑controlled phase 2 trial

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Galvokimig
  • Sponsor:UCB Biopharma

Phase 2 Study of Inhaled AGMB-447 and Salbutamol Sulfate in Adults with Idiopathic Pulmonary Fibrosis to Evaluate Lung Function, Safety and Tolerability

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol Sulfate
  • Sponsor:Agomab Spain S.L.

Non-small cell lung cancer

Not yet recruiting

Phase III Study of Izalontamab Brengitecan with Drug Combination versus Osimertinib Alone in First‑Line EGFR‑Mutated Advanced or Metastatic Non‑Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Breast cancer+2

Not yet recruiting

Gedatolisib with drug combination versus standard therapy as first‑line treatment for patients with advanced HR‑positive HER2‑negative breast cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Celcuity Inc.

Adenocarcinoma gastric+1

Not yet recruiting

A Phase 3 Study of ASP2138 Plus Drug Combination in Adults with HER2‑Negative, CLDN18.2‑Positive Advanced Gastric Cancer (First‑Line Treatment)

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Osimertinib and drug combination in metastatic non‑small cell lung cancer with targetable genomic driver alterations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Universita' Degli Studi Di Torino

VEXAS syndrome

Not yet recruiting

A Randomized, Double‑Blind, Placebo‑Controlled Study of Momelotinib Dihydrochloride Monohydrate in Patients with VEXAS Syndrome

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Momelotinib Dihydrochloride Monohydrate
  • Sponsor:Glaxosmithkline Research & Development Limited

Safety and Efficacy of Extended‑Release Tacrolimus (VI‑0106) in Adults with Pulmonary Arterial Hypertension and Functional Limitations

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Tacrolimus
  • Sponsor:Vivus B.V.

Comparison of nivolumab drug combination versus immunotherapy‑TKI sequence in patients with metastatic renal cell carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Acute myeloid leukaemia+2

Not yet recruiting

Safety and tolerability study of S-241656 with posaconazole in patients with AML, MDS/AML or CMML

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Posaconazole
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Piacenza

What the registry says about research in the country

01 Hematological Malignancies

Innovative clinical trials focusing on chronic myeloid leukemia, lymphomas, and various blood cancers, evaluating targeted therapies and combination treatments.

  • BCR-ABL1+ CML Treatment
  • Follicular Lymphoma Studies
  • Acute Myeloid Leukemia Research

Research emphasizes personalized treatment approaches and maintenance strategies for better patient outcomes.

02 Solid Tumors

Studies investigating advanced treatments for lung cancer, breast cancer, and pancreatic cancer, with focus on targeted and immunotherapy approaches.

  • NSCLC Treatment Sequences
  • Breast Cancer Hormone Therapy
  • Pancreatic Adenocarcinoma Studies

Trials explore novel drug combinations and treatment sequencing strategies.

03 Gynecologic Oncology

Clinical research examining treatments for ovarian cancer and related conditions, testing innovative therapeutic approaches and maintenance strategies.

  • Epithelial Ovarian Cancer
  • Fallopian Tube Cancer
  • Peritoneal Cancer Studies

Focus on hormone receptor-positive cancers and targeted treatment combinations.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.